SFN

American Medical Staffing, Inc. Appoints Linda Perneau as Chief Executive Officer

Retrieved on: 
Wednesday, March 27, 2024
SFN, HR, Growth, Sale, HUNT, Senior, Randstad, AMS, Marketing, Management

HUNT VALLEY, Md., March 27, 2024 /PRNewswire/ -- American Medical Staffing, Inc. ("AMS"), a leading provider of staffing solutions for the healthcare and education industries, announced the appointment of Linda Perneau as Chief Executive Officer, effective March 25, 2024.

Key Points: 
  • HUNT VALLEY, Md., March 27, 2024 /PRNewswire/ -- American Medical Staffing, Inc. ("AMS"), a leading provider of staffing solutions for the healthcare and education industries, announced the appointment of Linda Perneau as Chief Executive Officer, effective March 25, 2024.
  • With an extensive background in staffing, and global recognition as a Top Executive in Staffing by Staffing Industry Analysts, Ms. Perneau brings over thirty years of experience and leadership to AMS.
  • Prior to Volt, she held executive positions at Randstad, and as Senior Vice President/Group Executive - East Region at SFN Group/Spherion Staffing, which was acquired by Randstad.
  • "We are thrilled to welcome Linda Perneau to AMS as CEO," said Rohan Saikia, Managing Director of Great Point Partners.

Vertiv Acquisition of CoolTera Ltd. Boosts Liquid Cooling Portfolio

Retrieved on: 
Monday, December 4, 2023
Software, Networks, Machinery, Professional Services, Hardware, Apps, Applications, Technology, Other Manufacturing, Data Analytics, Engineering, Other Technology, Manufacturing, CDU, Ecosystem, AI, Acquisition, NYSE, SFN, Intellectual property, VRT, Vertiv

Founded in 2016 and based in the UK, CoolTera provides liquid cooling infrastructure solutions, and designs and manufactures coolant distribution units (CDU), secondary fluid networks (SFN), and manifolds for data center liquid cooling solutions.

Key Points: 
  • Founded in 2016 and based in the UK, CoolTera provides liquid cooling infrastructure solutions, and designs and manufactures coolant distribution units (CDU), secondary fluid networks (SFN), and manifolds for data center liquid cooling solutions.
  • CoolTera and Vertiv have been technology partners for three years with multiple global deployments to data centers and super compute systems.
  • CoolTera has a proven track record of engineering excellence and strong customer service supported by a team of highly qualified, proven liquid cooling engineers.
  • Vertiv is well-positioned to support the industry growth.”
    The acquisition is expected to close in the fourth quarter of 2023, subject to customary closing conditions.

Nitrase Therapeutics Announces Presentation at the SFN Neuroscience 2023 Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Therapy, SFN, Enzyme, Annual general meeting, Pharmaceutical industry

BRISBANE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new class of enzymes discovered in-house that are involved in a broad variety of diseases, today announced that Irene Griswold-Prenner, Ph.D., founder, chief executive officer and chief scientific officer of Nitrase Therapeutics will discuss the discovery and therapeutic potential of nitrases to treat Parkinson’s disease in a presentation at the SFN Neuroscience 2023 Annual Meeting held from November 11-15, 2023 in Washington, DC.

Key Points: 
  • BRISBANE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new class of enzymes discovered in-house that are involved in a broad variety of diseases, today announced that Irene Griswold-Prenner, Ph.D., founder, chief executive officer and chief scientific officer of Nitrase Therapeutics will discuss the discovery and therapeutic potential of nitrases to treat Parkinson’s disease in a presentation at the SFN Neuroscience 2023 Annual Meeting held from November 11-15, 2023 in Washington, DC.
  • Poster presentation details as follows:
    Identification of Synuclein Nitrase, one of a new class of enzymes, and a new target for Parkinson’s disease therapeutics

Schneider Electric doubles down on sustainable, digital industrial transformation at Hannover Messe

Retrieved on: 
Wednesday, April 12, 2023
Breakfast, Industrial internet of things, Maintenance, The Industries of the Future, CET, Life, Face, Atmosphere, Software, Tesis, Electricity, Process optimization, HMI, History, Carbon, Consultant, Spatial, Uninterruptible power supply, AVEVA, C46, GM, Digital transformation, Engineering, Hannover Messe, Schneider Electric, Linux, IEC, UPS, ETAP, SFN, CO2, Pampers, Video game, Renewable energy, Music, Hospitality industry, Telescopic sight, Microsoft Windows, Automation

Hannover Messe is the world's premier trade fair for industry, and it takes place in Hannover, Germany, from April 17 to 21 this year.

Key Points: 
  • Hannover Messe is the world's premier trade fair for industry, and it takes place in Hannover, Germany, from April 17 to 21 this year.
  • The innovations Schneider Electric is announcing at the event span its IoT-enabled, plug-and-play, open, interoperable architecture and platform, EcoStruxure, to drive efficiency in industries.
  • Services: Schneider Electric's experts and consultants will be on hand to share details about the company's refreshed services portfolio, including the newly-launched Industrial Digital Transformation Service which helps industrial companies accelerate their digital transformation.
  • Smart factory experiences: Tours through Schneider Electric Smart Factories and supply chain with live streams direct from the factory floors.

Red House Streaming Launches 'RHStv Connecting Tampa Bay' Streaming Network

Retrieved on: 
Thursday, March 2, 2023
Diamond, Commonwealth Youth New Zealand, SFN, Android, Roku, Amazon Fire TV, ABC, IOS, Sport, The Lighter Side of Sports, FAST, Health, Smart TV, House, Google Play, Organization, Apple TV, Family, Heitmann, RHS, Connected, Android TV, Petersburg, Apple Store, Social media, Privacy, Education, Comparison of multi-paradigm programming languages, VOD, WFLA-TV, NBC, Amazon Fire, Red House, Red, Television, Human, Mobile phone, Music, Online shopping

Tampa's first streaming network capable of reaching more than 1 million viewers offers a socially responsible approach to media and community engagement

Key Points: 
  • St. Petersburg, Florida--(Newsfile Corp. - March 2, 2023) - Red House Streaming, a subsidiary of CP Communications, officially launched RHStv Connecting Tampa Bay, a homegrown, advertising-supported streaming network with a growing lineup of original topic-driven programming, on February 2.
  • RHStv Connecting Tampa Bay represents the next phase of CEO Kurt Heitmann's vision to grow the Red House Streaming (RHS) business into a full-service video production and media delivery company.
  • The RHStv Connecting Tampa Bay launch now adds broadcast-quality programming for Connected TV platforms to Red House Streaming's creative services and technology portfolio.
  • RHStv Connecting Tampa Bay has already attracted local sponsors, including Golden Diamond Source and Tactical Rehab, for its program lineup.

NEURELIS ANNOUNCES FILING OF ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT CEREBRAL CAVERNOUS MALFORMATIONS

Retrieved on: 
Monday, January 9, 2023
Cerebral edema, Intracerebral hemorrhage, Stroke, Headache, Traffic barrier, Food, Hemangioma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Drug discovery, Frostbite, SFN, Brain, SAN, Trial of the century, Animal, Disease, Patient, Intracranial hemorrhage, Medical Affairs Bureau, Spinal cord, Seizure, Safety, Cerebral cortex, FDA, IND, CCMS, Conference, Bleeding, Human, CCM, ROCK, Medical imaging, Pharmaceutical industry, Neuroscience, Gustav Neuring

"Following favorable preclinical study results, we are excited to advance our mission to introduce new treatment options for patients with critical unmet medical needs."

Key Points: 
  • "Following favorable preclinical study results, we are excited to advance our mission to introduce new treatment options for patients with critical unmet medical needs."
  • Following the IND filing, the Company plans to initiate a clinical study evaluating the safety of NRL-1049 in early 2023.
  • CCMs are a disease characterized by abnormally enlarged capillary cavities, most commonly found in the cerebral cortex, brainstem, and spinal cord.
  • Most cavernous malformations are conservatively managed by observing for changes in appearance, recent hemorrhages, or other clinical symptoms.

SFN Announces Bizen Foundry Network That Halves IC Purchasing Price and Slashes Leadtime

Retrieved on: 
Tuesday, November 29, 2022
Technology, Other Manufacturing, Semiconductor, Manufacturing, CMOS, IC, Social media, ZTL, JMP, Silicon, SFN, SPICE, Mechanics, ITM, ICS, Synopsis, Electronic component, Mobile phone, Cadence, Next

By installing our ITM180 process node infrastructure, semiconductor foundries could easily offer their customers savings of 50% on the price of a device.

Key Points: 
  • By installing our ITM180 process node infrastructure, semiconductor foundries could easily offer their customers savings of 50% on the price of a device.
  • Bizen ZTL chips require fewer processing layers than CMOS, enabling complex devices to be manufactured in large-geometry fabs around the world.
  • Although a new technology, the Bizen process can run on standard silicon process technologies using standard CMOS processing equipment.
  • For more details about Bizen, ZTL and SFN, please visit https://www.wafertrain.com/blog , or join in the discussions at https://www.wafertrain.com/discussions , or on social media:

Cerevance Announces Presentation of Preclinical Study Results at the Society for Neuroscience Conference

Retrieved on: 
Tuesday, November 15, 2022
Cell, Neuroinflammation, Antibody, RNA, Factor X, Patient, Society, NLRP3, FACS, Protein, Central nervous system, Microglia, GPR6, SFN, CNS, Bracewell probe, Neurodegeneration, Gene expression, Membrane protein, Neuron, Pharmaceutical industry, Vaccine, Cerev Del

BOSTON, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, announced the presentation of preclinical study results during the poster session held November 14th at the Society for Neuroscience (SFN) 2022 conference in San Diego, California.

Key Points: 
  • NETSseq is a powerful tool to identify previously unelucidated drug targets for the development of novel therapies.
  • Key highlights of the presentation include:
    Using NETSseq, tandem pore domain halothane-inhibited potassium channel 1 (THIK-1) demonstrated significantly restricted gene expression in microglia which is increased in Alzheimers diseased human brain samples.
  • Overall, the data demonstrate the promise of blocking the target THIK-1 with molecules such as C101248 for the treatment of Alzheimers disease.
  • These probes tag specific cell types in brain tissue to enable the sorting of nuclei using fluorescence-activated cell sorting (FACS).

Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate

Retrieved on: 
Monday, November 14, 2022
Psilocybin, Psilocin, MSET, CSE, Mouse, EC50, BT, Pathology, Society for Neuroscience, FSE, Pharmacokinetics, ED50, Otsuka Pharmaceutical, LMA, Prodrug, Safety, Society, RATS, Depression, CSO, Development, Drug discovery, Behavior, SC, SFN, Patient, Pharmaceutical industry, Emax, Mindset, Neuroscience

Joseph Araujo, Chief Scientific Officer, Director of Mindset Pharma, presented the findings at Neuroscience 2022 hosted by the Society of Neuroscience (SfN) in a poster titled The Preclinical Safety, Behavioural and Pharmacokinetics Properties of MSP-1014, a Novel Prodrug of Psilocin .

Key Points: 
  • Joseph Araujo, Chief Scientific Officer, Director of Mindset Pharma, presented the findings at Neuroscience 2022 hosted by the Society of Neuroscience (SfN) in a poster titled The Preclinical Safety, Behavioural and Pharmacokinetics Properties of MSP-1014, a Novel Prodrug of Psilocin .
  • Psilocybin is a dihydrogen phosphonate prodrug of psilocin, which is thought to mediate antidepressant effects primarily by activation of 5-HT2A receptor subtype.
  • MSP-1014 was also evaluated in a drug discrimination assay in which rats were trained to discriminate a psilocybin cue from saline.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.

Nitrase Therapeutics Presented Data on the Importance of Synuclein Nitrase on the Synaptic Activity of Differentiated Dopaminergic Neurons at the Society for Neuroscience (SFN) Conference

Retrieved on: 
Monday, November 14, 2022
Enzyme, IPSC, Survival, Investment, Poster, Sofinnova, Idas, Therapy, Cancer, Solubility, MJFF, FPD, Dopamine, Society, SFN, Bristol Myers Squibb, Growth, Neuron, PFF, Alpha-synuclein, Pathology, The Michael J. Fox Foundation, Patient, Pharmaceutical industry, PD

BRISBANE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new class of enzymes discovered in-house that are involved in a broad variety of diseases, today announced the company presented the poster titled “Synuclein Nitrase, a Novel Enzyme that Catalyzes Nitration of Synuclein, Modulates Dopaminergic Neuron Activity” (abstract #110.04 / B29) at the Society for Neuroscience 2022 (SFN) conference held from November 12-16, 2022 in San Diego, CA.

Key Points: 
  • In preclinical studies, Nitrase examined the effect of knocking out Synuclein Nitrase on the survival, growth and electrical activity of differentiated dopaminergic neurons (iDAs) derived from human iPSC lines from both non-PD and familial PD (fPD) patients.
  • Knocking out Synuclein Nitrase also reduced synuclein accumulation in the insoluble fraction of preformed fibril (PFF) treated iDAs.
  • These studies establish that reducing Synuclein Nitrase levels can reduce electrophysiological deficits and insolubility of synuclein in PD iDA neurons.
  • These data demonstrate that targeting Synuclein Nitrase could serve as a novel disease-modifying therapeutic for patients with Parkinsons disease.